To review the contemporary landscape regarding pharmacological treatments for schizophrenia.
Method:
Selective literature review.
Results:
Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required.
Conclusions:
Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a ‘quantum leap’ agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.
LambertTJRCastleDJ. Pharmacological approaches to the management of schizophrenia. Med J Austr2003; 178: S57–61.
2.
WelgeJAKeckPE. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacol2003; 166: 1–10.
3.
McGorryP. At issue: Cochrane, early intervention, and mental health reform: analysis, paralysis, or evidence-informed progress?Schizophrenia Bull2012; 38: 221–224.
4.
LeuchtSKomossaKRummel-KlugeC. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry2009; 166: 152–163.
5.
Rummel-KlugeCKomossaKSchwarzS. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bull2010; 38: 167–177.
6.
CrossleyNAConstanteMMcGuireP. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Brit J Psychiatry2010; 196: 434–439.
7.
KishimotoTAgarwalVKishiT. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molec Psychiatry2013; 18: 53–66.
8.
LeuchtSHeresJHarmannJ. Methodological issues in current antipsychotic drug trials. Schizophrenia Bull2008; 34: 275–285.
9.
LeuchtSKisslingWDavisJM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med2009; 39: 1591–1602.
10.
LiebermanJAStroupTSMcEvoyJP. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Eng J Psychiat2005; 353: 1209–1223.
11.
BickPKnoesenNCastleDJ. Clinical implications of the CATIE trials for schizophrenia. Australas Psychiat2007; 15: 465–469.
12.
JonesPBBarnesTRDaviesL. Randomised controlled trial of the effect of quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiat2006; 63: 1079–1087.
13.
KahnRSFleischhackerWWBoterH. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet2008; 371: 1085–1097.
14.
LewisS. Second-generation antipsychotics: a therapeutic downturn?Psychol Med2009; 39: 1603–1606.
15.
SachdevPS. The current status of tardive dyskinesia. Austr NZ J Psychiat2000; 34: 355–369.
16.
StahlS. Essential psychopharmacology. 3rd ed. New York: Cambridge University Press, 2012.
17.
BazireS. Psychotropic drug directory 2012. Warwickshire, UK: Lloyd Reinhold, 2012.
18.
CastleDCopolovDWykesTMueserK, eds. Pharmacological and psychosocial treatments in schizophrenia. 3rd ed. London: Informa Healthcare, 2012.
NewtonRHustigHLakshmanaR. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr Med Res Op2012; 28: 559–567.
21.
MorganVWaterreusAJablenskyA. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Austr NZ J Psychiat2012; 46: 735–752.
22.
GalletlyCFoleyDWaterreusA. Cardiometabolic risk factors in people with psychosis: the second Australian national survey of psychosis. Austr NZ J Psychiat2012; 46: 753–761.
23.
CooperJMancusoSBorlandR. Tobacco smoking among people with a psychotic illness: the second Australian national survey of psychosis. Austr NZ J Psychiat2012; 46: 851–863.
24.
YoodMUDeLorenzeGQuesenberryCP. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Safety2009; 18: 791–799.
25.
BakerARichmondRCastleD. Coronary heart disease risk reduction intervention among overweight smokers with a psychotic disorder: a pilot trial. Austr NZ J Psychiat2009; 43: 129–135.
26.
WuR-RJinHKemingG. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomised, placebo-controlled study. Am J Psychiatry2012; 169: 813–821.
27.
TiihonenJLonnqvistJWahlbeckK. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet2009; 374: 620–627.
ZinkMEnglischSMeyer-LindenbergA. Polypharmacy in schizophrenia. Curr Op Psychiatry2010; 23: 103–111.
30.
TaylorDMSmithL. Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scand2009: 119: 419–425.
31.
JosiassenRCJosephAKohegyiE. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry2005; 162: 130–136.
32.
ChangJSAhnYMParkHJ. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry2008; 69: 720–731.
33.
FleischackerWWHeikkinenMEOlieJP. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol2010; 12: 1115–1125.
34.
AssionHJReinboldHLemanskiS. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiat2008; 41: 24–28.
35.
Van SantSBuckleyP. Pharmacotherapy for treatment-refractory schizophrenia. Expert Op Pharmacother2011; 12: 411–434.
36.
TiihonenJWahlbeckKKivineimeV. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res2009; 109: 10–14.
37.
CorrellCURummel-KlugeCCorvesC. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bull2009; 35: 443–457.
38.
BuckleyPMillerBJLehrerDS. Psychiatric comorbidities in schizophrenia. Schizophrenia Bull2009; 35: 383–402.
39.
BosanacPCastleD. Schizophrenia and depression. Med J Austr2012; 4: S36–39.
40.
MarsmanAVan den HeuvelMPKlompDWJ. Glutamate in schizophrenia: a focussed review and meta-analysis of [1]H-MRS studies. Schizophrenia Bull20113; 39: 120–129.
41.
PatilSTZhangLMartenylF. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomised Phase 2 clinical trial. Nat Med2007; 13: 102–1107.
42.
HarrisonPJ. Metabotropic glutamate receptor agonists for schizophrenia. Brit J Psychiatry2008; 192: 86–87.
43.
HechtEMLandyDC. Alpha-2-receptor add-on therapy in the treatment of schizophrenia: a meta-analysis. Schizophr Res2011; 134: 202–206.
44.
BymasterFPShannonHERasmussenK. Potential role of muscarinic receptors in schizophrenia. Life Sci1999; 64: 527–534.
45.
HenquetCSewellAKuepperR. The acute effects of cannabinoids in patients with schizophrenia. In: CastleDMurrayRMD’SouzaCD (eds) Marijuana and madness. 2nd ed. Cambridge: Cambridge University Press, 2012; 198–209.
